Business
IONIS PHARMACEUTICALS INC: We currently sell TEGSEDI in Europe through our distribution agreement with Swedish Orphan Biovitrum AB, or Sobi.
Revenue increased 33.8% to $943.7M, while Net income increased 16.0% to ($381.4M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $943.7MWatch
- Profitability — Net income ($381.4M)Watch
- Cash generation — Free cash flow ($320.0M)Note
- Accounting — Formula distress score · manipulation screen not computed · earnings quality safeWatch
- Insiders — 0 buys; 105 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as IONIS PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Research And Development Revenue$507.9M
- Collaborative Agreement Revenue$465.8M
- Commercial$435.8M
- Royalty$285.5M
- Spinraza Royalties$212.3M
Leadership changes
From IONIS PHARMACEUTICALS INC's own filings, the day they're filed.
- Peter N. Reikes · Director · appointmenteff. 2026-06-04
- Ludwig N. Hantson · chief executive officer · appointmenteff. 2026-06-04
- Joseph H. Wender · Directors · departureeff. 2026-03-03
Latest filings
- 8-K · Company announcement2026-07-29
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-10
- 8-K · Company announcement2026-07-09
- 8-K · Company announcement2026-06-24
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about IONIS PHARMACEUTICALS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.